684 related articles for article (PubMed ID: 8409438)
1. Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor- and host-specific alloantigens.
Cohen P; Vourka-Karussis U; Weiss L; Slavin S
J Immunol; 1993 Nov; 151(9):4803-10. PubMed ID: 8409438
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
3. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
5. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of graft-vs.-leukemia activity after depletion of CD3+ T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT).
Uharek L; Glass B; Zeis M; Dreger P; Steinmann J; Löffler H; Schmitz N
Exp Hematol; 1998 Feb; 26(2):93-9. PubMed ID: 9472798
[TBL] [Abstract][Full Text] [Related]
7. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
8. Effect of graft-versus-host disease on anti-tumor immunity.
Schreiber KL; Forman J
J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
[TBL] [Abstract][Full Text] [Related]
9. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
10. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic versus syngeneic killer splenocytes as effector cells for the induction of graft-versus-tumor effect.
Morecki S; Yacovlev E; Gelfand Y; Vilensky A; Slavin S
Biol Blood Marrow Transplant; 2004 Jan; 10(1):40-8. PubMed ID: 14752778
[TBL] [Abstract][Full Text] [Related]
12. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
13. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.
Uharek L; Glass B; Gaska T; Zeiss M; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S57-60. PubMed ID: 8124260
[TBL] [Abstract][Full Text] [Related]
15. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitivity and responsiveness to recombinant interleukin-2 of effector cells of graft vs. host disease and mixed lymphocyte reaction in mice.
Stark J; Weiss L; Slavin S
Isr J Med Sci; 1992 Nov; 28(11):767-72. PubMed ID: 1468887
[TBL] [Abstract][Full Text] [Related]
17. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
Thiele DL; Calomeni JA; Lipsky PE
J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
[TBL] [Abstract][Full Text] [Related]
18. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
19. The role of antibodies to IL-2 receptor and Asialo GM1 on graft-versus-leukemia effects induced by bone marrow allografts in murine B cell leukemia.
Weiss L; Reich S; Slavin S
Bone Marrow Transplant; 1995 Sep; 16(3):457-61. PubMed ID: 8535320
[TBL] [Abstract][Full Text] [Related]
20. CD3+ T cells in severe combined immunodeficiency (scid) mice. IV. Graft-vs.-host resistance of H-2d scid mice to intravenous injection of allogeneic H-2b (C57BL/6) spleen cells.
Claesson MH; Rudolphi A; Tscherning T; Reimann J
Eur J Immunol; 1991 Sep; 21(9):2057-62. PubMed ID: 1832384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]